The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom

In the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose QIV (QIV-HD) are preferred for persons aged 65 years and older but only aQIV is reimbursed by the National Health Service (NHS). The objective was to determine the potential cost-effectivenes...

Full description

Bibliographic Details
Main Authors: Michele A. Kohli, Michael Maschio, Joaquin F. Mould-Quevedo, Michael Drummond, Milton C. Weinstein
Format: Article
Language:English
Published: Taylor & Francis Group 2021-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
influenza vaccine
cost-effectiveness
economic modeling
Online Access:http://dx.doi.org/10.1080/21645515.2021.1971017

Internet

http://dx.doi.org/10.1080/21645515.2021.1971017

Similar Items